Genetic tests

In April 2025, the National Institute for Health and Care Research (NIHR) in England released five Med Tech-related assessments in its HTA Journal, which concerned the evaluation of prognostic models of metastasis in colorectal cancer, assessment of e-Health platform for low back pain and the results of the “CONtact TrAcing in Care homes using digital Technology” trial. HTA Journal publishes research reports on the effectiveness, costs, and broader impact of health technologies for those who use, manage, and provide care in the NHS, and informs NICE guidance.

On April 14, 2025, the National Board of Health and Welfare was tasked to allocate 80 million SEK from the government to support Genomic Medicine Sweden (GMS) project in 2025. Funding will be distributed to several projects, including the development and/or implementation of innovative technologies such as whole genome sequencing based on long DNA reads, gene panels for sensitive detection of residual disease, and precision diagnostics (liquid biopsies for solid tumors, detection of antibiotic resistance).

In March 2025, the Draft Order amending the Common Package of Benefits of the National Health System and some other related legislative orders were released for public consultation. The Draft Order focuses on updating public health and primary care services, expanding neonatal and cancer screenings, improving equity in access to in-vitro fertilization, refining rehabilitation definitions, including patients in genetic advisory bodies, and modifying the system for ortho-prosthetic products.

In February and March 2025, the Common Catalog of Genetic and Genomic Tests of the National Health System was updated in Spain. A new section, “Hepatic diseases,” was added, including 24 tests for multiple hepatic diseases.

In January 2025, the Common Catalog of Genetic and Genomic Tests of the National Health System was updated in Spain. A new section, “Respiratory medicine,” was added, including 29 tests for multiple respiratory diseases.

In November 2024, the Galician Agency for Health Technology Assessment (AVALIA-T) is working on several HTAs, including in cardiovascular, e-health, ICU/OR, in-vitro diagnostics, neurology and neurosurgery, neuromodulation, orthopedics, pulmonary and airways, radiotherapy, surgical procedures, and some other fields.

On October 31, 2024, the Swiss Federal Statistics Office (UFS) released the systematic version of the procedure code (CHOP) nomenclature for 2025. The nomenclature is now available in German, Italian, and French languages and will come into force on January 1, 2025. Multiple new procedure codes were introduced in various fields, including endoscopy, extracorporeal treatments, in-vitro diagnostics, interventional radiology, obstetrics and gynecology, orthopedics, and radiotherapy.

In October 2024, the National Institute for Health and Care Research (NIHR) in England released seven Med Tech-related assessments in its HTA Journal, which concerned the Genedrive kit, timing of stoma closure in neonates, interventions in perceptual disorders after stroke, revascularisation strategy for chronic limb ischemia, MRI software and cognitive fusion biopsies in prostate cancer, transperineal prostate biopsy devices, and ultraviolet therapy in severe eczema. HTA Journal publishes research reports on the effectiveness, costs, and broader impact of health technologies for those who use, manage, and provide care in the NHS and informs NICE guidance.

In late October 2024, the Agency for Health Technology Assessment and Tariff System (AOTMiT) published several recommendations concerning the Prenatal Testing Program, specifically on removing alpha-fetoprotein and estriol testing and qualifying the placental growth factor (PlGF) test and free fetal DNA testing (cffDNA) as part of non-invasive prenatal diagnostics.

On October 9, 2024, the new version of the Nomenclature of Medical Biology Procedures (NABM 93) was released in France. Changes included the introduction of five new codes and wording modifications for several codes.

In September 2024, the National Institute for Health and Care Research (NIHR) in England released three MedTech-related assessments in its Health Technology Assessment (HTA) Journal, which concerned hyperthermic intraoperative peritoneal chemotherapy and cytoreductive surgery in peritoneal metastases, resuscitative endovascular balloon occlusion of the aorta in life-threatening torso hemorrhage, and clopidogrel resistance genotype testing. HTA Journal publishes research reports on the effectiveness, costs, and broader impact of health technologies for those who use, manage, and provide care in the NHS and informs National Institute for Health and Care Excellence (NICE) guidance.

On September 6, 2024, the new version of the Nomenclature of Medical Biology Acts (NABM 92) was released in France. Various changes were implemented, including the introduction of one new code, modification of the coefficient B rating for a number of codes, and deletion of Article 4 "Minimum quotations" from the general provisions section of the NABM with 18 codes of this section.